Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Celcuity Inc.NASDAQ: CELC

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses remains negative

Q2 FY2026 other income / expenses was -$12.75M, compared with -$1.26M a year earlier. Trailing-twelve-month other income / expenses was -$17.81M.

Context

  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$12.75M or moves back toward the trailing-twelve-month quarterly average of -$4.45M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$12.75M-446.1% QoQ
Last fiscal yearDec 2025
-$4.85M-426.0% YoY
LTMJun 2026
-$17.81M-757.0% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-912.4%——
1 year-426.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(4.85M) USD
Year-over-year change
-426.0%

Other Income / Expenses vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's LTM Jun 2026 other income / expenses of -$17.81M is the 5th highest of the 6 companies compared; the peer median is $7M.
  • Its year-over-year change of -757.0% is the 5th highest of 6, against a peer median of +21.0%.
CELC Competitors Peer median
Other Income / Expenses for CELC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CSTLCastle Biosciences, Inc.LTM Mar 2026$15.63M +35.1%+49.9%4.6%
NEONeoGenomics, Inc.LTM Jun 2026$11.62M +21.0%—1.5%
PSNLPersonalis, Inc.LTM Mar 2026$7M +141.3%+44.5%10.9%
BLLNBillionToOne, Inc.LTM Jun 2026-$5.4M -144.3%—1.4%
CELCCelcuity Inc.LTM Jun 2026-$17.81M -757.0%——
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026-$26.55M -21309.7%—8.6%
Peer median (excluding CELC) $7M+21.0%+47.2%4.6%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000167K
Gross Profit0000(167K)
Gross Margin—————
Research & Development25.76M35.29M60.59M104.2M145M
Selling, General & Admin2.6M4.38M5.64M9.06M27.2M
Operating Expenses28.36M39.39M66.23M113.27M172.19M
Depreciation & Amortization303.24K210.92K142.77K129.95K167K
EBITDA(28.04M)(38.05M)(58.31M)(101.37M)(159.73M)
EBITDA Margin—————
Operating Income(28.36M)(39.39M)(66.23M)(113.27M)(172.19M)
Operating Margin—————
Interest Income13.26K1.13M7.78M11.77M12.3M
Interest Expense1.26M2.11M5.33M10.28M17.15M
Other Income / Expenses(1.25M)(978.95K)2.45M1.49M(4.85M)
Income Before Tax(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(29.61M)(40.37M)(63.78M)(111.78M)(177.04M)
Net Margin—————
EPS (Basic)(2.28)(2.68)(2.69)(2.83)(3.78)
EPS (Diluted)(2.28)(2.68)(2.69)(2.83)(3.78)
Weighted Avg Shares13.38M15.42M23.68M39.45M52.54M
Weighted Avg Shares (Diluted)13.38M15.42M23.68M39.45M52.54M

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.